Entries tagged "Jon Leibowitz"
The FTC tries finally to end Generics' pay-for-delay Deals with branded pharma. But will it survive the healthcare reform?
FTC Chairman Jon Leibowitz has urged Congress to pass controversial legislation amending the antitrust laws to prohibit 'reverse payment' or 'pay for delay' patent settlements between branded and generic pharma companies.
The return of tech dealmaking brings with it a revived threat of scrutiny.
The deal slowdown offers antitrust regulators an opportunity to rework merger guidelines.
The new president and his economic team face daunting issues that leave no time for dallying. Here are some clues for what to expect in the early days of the Barack Obama administration.
